scout

Breast Cancer

Latest News


CME Content


Based on a keynote address given by Marie Overgaard, md, at the 1998 American Society for Therapeutic Radiology and Oncology (ASTRO) meeting. Dr. Overgaard is consulting oncologist, Aarhus University Hospital, Denmark, as

ORLANDO-Breast cancer patients whose tumors respond to induction chemotherapy and who have no clinical axillary node disease following induction may be safely treated with axillary irradiation rather than axillary lymph node dissection, Jeffrey Lenert, MD, said at the Society of Surgical Oncology’s Annual Cancer Symposium.

ALEXANDRIA, Va-Preliminary findings from four of five randomized studies show no survival advantage for high-dose chemotherapy/autologous bone marrow transplantation (HDC/ABMT) in breast cancer patients with metastatic or high-risk disease (10 or more positive axillary lymph nodes), researchers said at an ASCO teleconference.

WASHINGTON-Sales of the 40-cent Breast Cancer stamp generated $5.2 million for breast cancer research in the first 7 months following its release in July 1998. The US Postal Service plans a sales campaign tied to Mother’s Day, and it will promote the stamp in partnership with the Revlon Run/Walk for Women fund-raiser in Los Angeles and New York City

HAMILTON, Ontario-A meta-analysis of published clinical trials, presented at the San Antonio Breast Cancer Symposium, supports the concept that locoregional radiation therapy after mastectomy in breast cancer patients treated with adjuvant systemic therapy reduces the risk of recurrence and improves overall survival.

COLUMBUS, Ohio-Chemopre-vention trials in recent years have led to new chemoprevention agents and also unexpected negative findings, Winfred F. Malone, PhD, MPH, said at the 4th Annual Congress of the Society for Nutritional Oncology Adjuvant Therapy (NOAT). He described a number of published and ongoing clinical trials.

FORT LAUDERDALE, Fla-With the first results from its Oncology Outcomes Database, the National Comprehensive Cancer Network (NCCN) has “taken a step to move beyond the guideline development process into a process of connection,” William McGivney, PhD, CEO of the network, said at its Fourth Annual Conference. “That critical step is the implementation of guidelines through performance measurement.”

HOUSTON-Stress is an immediate reaction to cancer that generally becomes more intensified during the course of the disease. Barbara L. Andersen, PhD, Department of Psychology, Ohio State University, Columbus, and her colleagues are conducting a study to examine the effects of stress on the immune system in cancer patients.

BETHESDA, Md-The National Cancer Institute (NCI) announced that preliminary findings from two long-awaited breast cancer studies are expected to be made available April 15 on the American Society of Clinical Oncology (ASCO) website (www.asco.org).

SAN ANTONIO-The addition of docetaxel (Taxotere) to the combination of doxorubicin (Adriamycin) and cyclophosphamide (AC) is an effective and safe first-line therapy for women with metastatic breast cancer, Jean-Marc A.Nabholtz, MD, said at a poster session of the 21st Annual San Antonio Breast Cancer Symposium.

FORT LAUDERDALE, FL-In a first-of-its kind, the American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) have collaborated to produce “Breast Cancer Treatment Guidelines for Patients,” a detailed translation for the public of NCCN’s breast cancer practice guidelines. The NCCN is a coalition of 17 leading US cancer centers. Its practice guidelines have won acceptance among many oncologists as the “gold standard” of treatment.

HAMBURG, Germany-“Significant numbers of women with breast cancer have psychological distress that goes unidentified,” said David Payne, PhD, of the Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center.

SAN ANTONIO-A long-term Dutch study has provided additional evidence that the duration of tamoxifen (Nolvadex) therapy influences the degree of benefit for reducing breast cancer recurrence. However, the optimal duration of therapy remains an open question, Dr. Jan Vermorken, an oncologist at University Hospital, Antwerp, said at the San Antonio Breast Cancer Symposium.

HAMBURG, Germany-“We need to help partners of women with breast cancer realize their role in helping their wives, express their concerns, and gain more information,” Barry Bultz, PhD, said at the Fourth International Congress of Psycho-oncology.